MARKET

KYNB

KYNB

KYNTRA BIO INC
NASDAQ
6.75
-0.31
-4.39%
After Hours: 6.75 0 0.00% 16:10 03/24 EDT
OPEN
6.96
PREV CLOSE
7.06
HIGH
7.05
LOW
6.64
VOLUME
50.27K
TURNOVER
--
52 WEEK HIGH
12.60
52 WEEK LOW
4.850
MARKET CAP
27.32M
P/E (TTM)
0.1488
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at KYNB last week (0316-0320)?
Weekly Report · 1d ago
FibroGen Earnings Call: Cash-Rich, Data-Heavy, Unproven
TipRanks · 03/18 00:05
Kyntra Bio Q4 And FY25 Revenue Declines; On Track For Phase 2 Trial Analysis Of FG-3246 In H2,2026
NASDAQ · 03/17 10:26
Advancing Pipeline and 2026 Clinical Catalysts Underpin Buy Rating on Kyntra Bio
TipRanks · 03/17 10:16
Maintaining a Hold on Kyntra Bio Amid Pipeline Refocus and Pending Clinical Inflection Points
TipRanks · 03/16 22:55
Kyntra Bio (KYNB) Q4 2025 Earnings Call Transcript
The Motley Fool · 03/16 22:08
Kyntra Bio Inc. publishes investor presentation on its prostate cancer FG-3246 and roxadustat programs and USD 220 million FibroGen China sale
Reuters · 03/16 20:25
*Kyntra Bio: Phase 2 Monotherapy Trial of FG-3246 Actively Enrolling and Remains on Track for Interim Analysis in 2H
Dow Jones · 03/16 20:22
More
About KYNB
Kyntra Bio, Inc., formerly FibroGen, Inc., is a biopharmaceutical company. The Company is focused on development of novel therapies in oncology and rare disease. The Company continues to evaluate the development plan for the Phase III trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase II development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. Roxadustat (EVRENZO) is approved in Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis.

Webull offers Kyntra Bio Inc stock information, including NASDAQ: KYNB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYNB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYNB stock methods without spending real money on the virtual paper trading platform.